Tamtam Try Tamtam free
Myriad Genetics logo

Myriad Genetics account plan

Molecular diagnostic testing company

At a glance

Myriad Genetics is a Salt Lake City molecular diagnostics company with $824.5 million FY2025 revenue in cancer, mental health and prenatal testing.

Myriad Genetics is a molecular diagnostics and precision medicine company headquartered in Salt Lake City, Utah, selling genetic tests to healthcare providers and health systems, paid by commercial payors, Medicare and patients. It sells mainly in the United States (U.S. revenue $768.0 million of $824.5 million in 2025) and Japan. FY2025 revenue fell 2% to $824.5 million on 1,537 thousand tests, and the net loss was $365.9 million, driven by $319.4 million of impairment charges. It had about 2,700 full-time equivalent employees at December 31, 2025. In October 2026 it agreed to sell its Prenatal Health business to Labcorp to focus on the Cancer Care Continuum and Mental Health.

Business units

Strategic priorities

Build the Cancer Care Continuum menu
Build a comprehensive test menu for the Cancer Care Continuum, prioritising high-growth applications such as Precise MRD; R&D investment is expected to increase in 2026 with a CCC focus.
Exit Prenatal Health
Sell Prenatal Health to Labcorp for $210 million cash plus inventory; management expects revenue growth to improve by over 100 basis points and gross margin by more than 500 basis points after the sale.
Grow Mental Health at or above market
Expand GeneSight with primary care and behavioral health clinicians, state biomarker laws and patient direct-payment options.
Restore profitable growth
The Ascend programme, run with a leading consulting firm, modernises processes, organisation and tools; management expects "meaningful progress in 2027" on profitability.
Push back on reimbursement pressure
Process improvements, "AI-enabled workflow acceleration" and a payer-by-payer market access strategy against rising denials in hereditary cancer testing.

Latest results

Q3 2026 revenue was $202.7 million, +6% sequentially and -1% year-over-year, as average revenue per test rose 7% sequentially while volume fell 2% year-over-year. Cancer Care Continuum revenue was $123.9 million (+1%) and GeneSight $39.5 million (+2%), while Prenatal Health fell 12% to $39.3 million. Gross margin was 67.9%, down 200 basis points, and the net loss widened to $43.9 million from $27.4 million; adjusted EBITDA was -$5.3 million. FY2026 revenue guidance was raised at the mid-point to $780-$790 million, of which Cancer Care Continuum and Mental Health $620-$630 million. Cash was $107.1 million at September 30, 2026.

Investments and deals

Prenatal Health divestiture
Definitive agreement of October 19, 2026 to sell Prenatal Health to Labcorp for $210 million cash plus inventory; proceeds may repay part or all of the OrbiMed loans, fund operations and invest in the Cancer Care Continuum.
OrbiMed term loan
July 2025 facility of $200.0 million, $125.0 million drawn, maturing July 2030, with a minimum trailing revenue covenant starting at $615.0 million.
Oncology partnerships
Exclusive U.S. rights to PATHOMIQ's AI prostate platform (Prolaris + AI launched mid-2026), a September 2025 liquid biopsy companion diagnostic collaboration with SOPHiA GENETICS, and an October 2026 SOPHiA GENETICS collaboration on a prostate genomic instability score with AstraZeneca.
Commercial organisation
Sales and marketing expense rose 18% to $83.9 million in Q3 2026, including $10.6 million more personnel cost from investment in the commercial organisation.
Ascend programme
A multi-year initiative with a leading consulting firm to modernise processes, organisation and tools, with more detail promised in 2027.

Challenges and risks

Reimbursement pressure
Hereditary cancer revenue per test is down on denials; management frames long-term per-test declines "of 1% to 5%, maybe skewing 3% to 5% most recently".
GeneSight coverage loss
UnitedHealthcare stopped covering GeneSight under its commercial, individual exchange and certain managed Medicaid plans, cutting Mental Health revenue 15% in 2025.
Losses and liquidity
Nine-month 2026 net loss of $121.2 million, an operating cash outflow of $30.5 million, and cash down to $107.1 million from $149.6 million, with a $125.0 million term loan at 10.2%.
Competition
Natera, Labcorp, Quest, Tempus, Guardant and others compete in oncology, women's health and mental health testing.
Single-site operations
Each test is processed in a single laboratory, with limited or single-source suppliers.

What leadership says

“continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stability”

Sam Raha, President and Chief Executive Officer · Q3 2026 earnings call, November 4, 2026, naming the three challenges

“a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum”

Sam Raha, President and Chief Executive Officer · Q3 2026 earnings release, November 4, 2026, on the Prenatal Health sale

“it has become increasingly clear that our prenatal testing business was unable to generate attractive returns in the near term”

Ben Wheeler, Chief Financial Officer · Q3 2026 earnings call, November 4, 2026

“quite frankly, we haven't lived up to our potential”

Sam Raha, President and Chief Executive Officer · Mendelspod podcast, September 16, 2025

Where a supplier can help

Revenue cycle and denial management
Reimbursement pressure from denials and the AI-enabled workflow and payer-by-payer access work make revenue cycle, appeals automation and market access services relevant.
Operating model modernisation
The Ascend programme to modernise processes, organisation and tools is a direct opening for process, workflow and productivity software.
Divestiture separation
The Prenatal Health sale to Labcorp, with about 500 employees moving, requires carve-out, systems separation and transition services.
Oncology commercial build-out
Investment in the commercial organisation and Precise MRD launches call for sales enablement, EMR integration and physician education support.
Cost discipline
Losses and a shrinking cash balance under a revenue covenant favour suppliers that lower laboratory and operating cost.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Myriad Genetics?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Myriad Genetics

What does Myriad Genetics do?

Myriad Genetics develops and sells molecular diagnostic tests that assess disease risk or progression and guide treatment, in cancer (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise MRD), mental health (GeneSight) and prenatal health, which it is selling to Labcorp.

What is Myriad Genetics' revenue?

FY2025 revenue was $824.5 million, down 2%. FY2026 guidance is $780-$790 million.

How many employees does Myriad Genetics have?

About 2,700 full-time equivalent employees at December 31, 2025; about 500 are expected to move to Labcorp with the Prenatal Health sale.

Who leads Myriad Genetics?

Sam Raha has been President and CEO since April 30, 2025, with Ben Wheeler as CFO and Mark Verratti as COO.

What is Myriad Genetics' strategy?

Accelerate profitable growth by building a comprehensive Cancer Care Continuum test menu, growing Mental Health at or above market and keeping financial and operational discipline, while exiting Prenatal Health.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)